|Bid||16.80 x 3000|
|Ask||16.74 x 800|
|Day's range||14.89 - 18.47|
|52-week range||1.92 - 33.79|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were bouncing back somewhat on Friday after Thursday's sharp decline. It's also possible that some short-sellers could be covering their positions before the weekend as a precaution in case Inovio announces good news before Monday. There seems to be a good chance that Inovio will have positive news to announce in the near future.
Shares of the developmental vaccine and immunotherapy company Inovio Pharmaceuticals (NASDAQ: INO) fell by as much as 15.8% right out of the gate Thursday morning. Investors seemingly piled into this biotech stock this week in the hopes of getting in before the company lands a large grant for its COVID-19 vaccine candidate, INO-4800. Not everyone was impressed by Inovio's investor presentation, however.
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were soaring 14.6% as of 11:02 a.m. EDT after jumping as much as 19.5% earlier in the day. This marked the third consecutive day of big gains for Inovio. Investors remain excited about comments made by Inovio CEO J. Joseph Kim at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday.